Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Exelixis and Merck Sharp & Dohme Corp.
Description:
Renal cell carcinoma (RCC) is a kidney cancer that originates in the
lining of the proximal convoluted tubule, a part of the very small
tubes in the kidney that transport waste molecules from the blood to
the urine. RCC is the most common type of kidney cancer in adults,
responsible for approximately 90–95% of cases. In 2020, it is
estimated that there will be approximately 73,750 new cases of
kidney cancer, and about 14,830 people will die from the disease.
Approximately 16% of patients with RCC will have metastases at
diagnosis, and as many as 40% will demonstrate metastasis after
primary surgical treatment for localized RCC. With a 5-year survival
rate ranging from 5% to 12%, the prognosis for these patients is
poor. Fortunately for patients with advanced RCC, several new
treatments, including targeted therapies and immunotherapies, have
recently become available giving clinicians new options to improve
patient outcomes and quality of life. Additionally, new combination
regimens comprised of multiple receptor tyrosine kinase inhibitors
and anti-PD-1 immunotherapies have shown improved efficacy and
safety in clinical trials. With so many new options becoming
available for the healthcare community, clinicians are struggling to
stay abreast of all the changes in advanced RCC treatment. It is
critical that medical directors, oncologists, nurses and other
healthcare professionals are updated on these emerging options and
strategies for implementing them into the treatment paradigm, which
will ultimately improve patient outcomes.
The prognosis for any treated renal cell cancer patient with
progressing, recurring, or relapsing disease is poor, regardless of
cell type or stage. Almost all patients with advanced renal cell
cancer are incurable. The question and selection of further
treatment depends on many factors, including previous treatment and
site of recurrence, as well as individual patient considerations.
Fortunately, clinicians have recently been equipped with more
options to integrate into the advanced RCC treatment paradigm,
including targeted therapies and immunotherapies, which
individualize therapy for patients with advanced RCC who have
progressed on prior therapies, ultimately improving patient outcomes
and quality of life. Additionally, multiple receptor tyrosine kinase
inhibitors and anti-PD-1 immunotherapies have been combined in
clinical trials with impressive results. These new options have
shown improved efficacy and safety in advanced RCC, and medical
directors, oncologists, nurses and other healthcare professionals
must be educated on these options and the potential risks that come
along with any new treatment option.
Upon completion of this
activity, participants will be able to:
-
Identify current unmet economic and
clinical needs in the management of advanced renal cell
carcinoma (RCC) and evidence-based recommendations for the care
of patients with these tumors
-
Examine the pathogenesis of RCC and
the scientific foundation for targeted therapies
-
Analyze recent efficacy and safety
data on single-agent and combination targeted therapies and
immunotherapies, as well as patient and disease characteristics
and patient preferences, as a part of shared decision-making for
patients with advanced RCC
-
Examine the role of targeted
therapies and immunotherapies in the first-line management of
advanced RCC
-
Explore strategies to monitor and
manage adverse events associated with targeted therapy and
immunotherapy options in advanced RCC in order to improve
patient adherence and quality of life
-
Discuss the managed care
considerations of current and emerging targeted therapies and
immunotherapies by exploring where these agents fit into the
current advanced RCC management paradigm
|
Faculty: |
Robert A. Figlin, MD,
FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Cedars-Sinai Cancer
Deputy Director, Samuel Oschin Comprehensive Cancer
Institute
Cedars-Sinai Medical Center |
|
Disclosure:
|
Dr. Figlin
serves on an advisory board for Appolomics, Eisai,
Exelixis and Merck. He has received grant/research
support from Calithera, Exelixis and Merck. His
presentation has been peer reviewed for any bias. |
|
|
Planning Committee:
Bill Williams,
MD has no real or perceived financial relationships to
disclose.
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
Exelixis and Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |